modelL03AB10
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | PeginterferonAlfa2b | |
| ATC code: | L03AB10 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 1.5 | mg |
| volume of distribution: | 0.99 | L |
| clearance: | 22 | mL/h/kg |
| other parameters in model implementation | ||
Peginterferon alfa-2b is a pegylated recombinant interferon used as an antiviral and antineoplastic agent, primarily in the treatment of chronic hepatitis C and B infections. It has also been explored in some malignancies. While widely used in the 2000s and 2010s, direct-acting antivirals have largely replaced it in hepatitis C therapy. It remains approved and is occasionally used today in specific settings.
Pharmacokinetics
Pharmacokinetic parameters in adult patients with chronic hepatitis C receiving subcutaneous doses.
References
Xu, C, et al., & Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. European journal of clinical pharmacology 69(12) 2045–2054. DOI:10.1007/s00228-013-1574-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23975236
Miyachi, N, et al., & Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. Clinical drug investigation 41(4) 391–404. DOI:10.1007/s40261-021-01026-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33725322
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)